This trial is active, not recruiting.

Condition acute myocardial infarction
Treatment blood sample
Sponsor Assistance Publique - Hôpitaux de Paris
Collaborator French Cardiology Society
Start date October 2005
End date December 2016
Trial size 3750 participants
Trial identifier NCT00673036, 04-1244


The Fast-MI registry was designed to evaluate the "real world" management of patients with acute myocardial infarction (MI), and to assess their in-hospital, medium and long-term outcomes

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Adults (female and male) with a acute coronary syndrome
blood sample
60 ml of whole blood

Primary Outcomes

All causes mortality at each follow-up period
time frame: 6 months, each year

Secondary Outcomes

Cardiovascular mortality
time frame: 6 month, each year
validation of guidelines across the country
time frame: 6 month, each year
Pharmacogenetic and cardiovascular genetic studies associated to clinical outcomes
time frame: 6 month each year
Serum databank for evaluation of biomarkers in MI
time frame: 6 month each year

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - admission within the 48 hours after the occurence of acute myocardial infarction (AMI) - written informed consent for the DNA and serum databank Exclusion Criteria: - AMI occured within the 48 hours after therapeutic intervention (bypass, coronary angioplasty or other chirurgical intervention) - diagnostic of AMI not confirmed

Additional Information

Official title French Registry of Acute Coronary Syndrome With or Without ST Elevation
Principal investigator Nicolas DANCHIN, MD PH
Description Primary objectives : compare survival following the admission to a USIC according to the terms of care
Trial information was received from ClinicalTrials.gov and was last updated in October 2015.
Information provided to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris.